PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies.

被引：0
|
作者：
Stinchcombe, TE
Mitchell, BS
Depcik-Smith, N
Adams, J
Elliott, P
Shea, TC
Orlowski, RZ
机构：
[1] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA
[2] Univ N Carolina, Chapel Hill, NC USA
[3] Millenium Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2219
引用
收藏
页码：516A / 516A
页数：1
相关论文
共 50 条
  • [1] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [2] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [3] Development of the proteasome inhibitor PS-341
    Adams, J
    ONCOLOGIST, 2002, 7 (01): : 9 - 16
  • [4] The proteasome inhibitor PS-341 in cancer therapy
    Teicher, BA
    Ara, G
    Herbst, R
    Palombella, VJ
    Adams, J
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2638 - 2645
  • [5] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
  • [6] Phase I study of the proteasome inhibitor bortezomib (PS-341, Velcade™) in combination with pegylated liposomal doxorubicin (Doxil®) in patients with refractory hematologic malignancies.
    Orlowski, RZ
    Hall, M
    Voorhees, P
    Hogan, C
    Humes, E
    Johri, A
    Bell, H
    Garcia, R
    Adams, J
    Esseltine, D
    Gabriel, D
    Shea, T
    Van Deventer, H
    Mitchell, B
    Dees, EC
    BLOOD, 2002, 100 (11) : 105A - 105A
  • [7] Proteasome inhibition by PS-341: A phase I study.
    Hamilton, A
    Eder, JP
    Pavlick, A
    Clark, JW
    Chachoua, A
    Ryan, DP
    Farrell, K
    Wasserstrom, H
    Liebes, L
    Wright, J
    Elliott, P
    Adams, J
    Muggia, F
    CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
  • [8] PS-341, a proteasome inhibitor for cancer treatment.
    Adams, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U665 - U665
  • [9] Current clinical trials for the proteasome inhibitor PS-341
    不详
    ONCOLOGY-NEW YORK, 2000, 14 (11): : 1589 - +
  • [10] The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.
    Mitsiades, N
    Mitsiades, CS
    Poulaki, V
    Fanourakis, G
    Chauhan, D
    Munshi, NC
    Hideshima, T
    Anderson, KC
    BLOOD, 2002, 100 (11) : 815A - 815A
12345